Search company, investor...

Valgen Medtech

Founded Year



Series B | Alive

Total Raised




Last Raised

$133M | 2 yrs ago

About Valgen Medtech

Valgen Medtech specializes in mitral valve disease treatment and related devices.

Headquarters Location

Hangzhou, Zhejiang , 310000,


Missing: Valgen Medtech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Valgen Medtech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Valgen Medtech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Valgen Medtech is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Unicorns- Billion Dollar Startups

1,201 items


Health IT

7,901 items

Latest Valgen Medtech News

China Marches into the Era of Interventional Direct Annuloplasty

Nov 5, 2022

USA - English Share this article Launching of the 1st Human Implantation of "DragonRing" – Catheter-based Mitral Annuloplasty Device HANGZHOU, China, Nov. 5, 2022 /PRNewswire/ -- On October 28, 2022, a multidisciplinary, and international cardiac team led by Professor Mao Chen from Department of Cardiology, West China Hospital, Sichuan University, successfully performed the world's first human implantation of "DragonRing", which is the first interventional transfemoral direct annuloplasty ring system innovated in China that simulates the atrioventricular annuloplasty technology from contemporary cardiac surgery. Completely and independently developed by Hangzhou Valgen Medtech Co., Ltd., DragonRing is designed to effectively treat functional mitral valve regurgitation by cinching the dilated annulus, particularly focusing on the patient population with atrial fibrillation as the primary etiology of their mitral regurgitation. Professor David Scott Lim, Director of the Advanced Cardiac Valve Center, University of Virginia, USA, Professor Azeem Latib, Section Head of Interventional Cardiology, Montefiore Medical Center, USA, and Professor Felix Kreidel, Head of the Department of Cardiology, Schleswig-Holstein University, Germany, conducted technique exchanges together with Professor Mao Chen's team through remote video conferencing. Valgen_Medtech "For atrial functional valve regurgitation, the design of the DragonRing device aims to replicate the surgical standard of care by reducing annular dilation, but in a minimally invasive way, with the advantage of allowing subsequent treatment with other interventional technologies if needed in the future. This First-in-Human experience is encouraging and we look forward to more data from the subsequent study of DragonRing," commented by Professor Scott Lim after the procedure. DragonRing is a novel technology developed for treating valvular regurgitation. Following the successful launches of "DragonFly" (transcatheter edge-to-edge repair system) and "MitralStitch" (transcatheter artificial chordae implantation system), Valgen Medtech continues its mission in making breakthroughs of interventional structural heart treatment techniques. Valgen is building its reputation with the comprehensive concept of "a Tool Box for structural heart diseases", with additional innovative "Dragon-" series catheter-based products in its pipeline, providing more options and possible technique combinations for future clinical practice, and pushing the boundaries of interventional treatment of structural heart disease into a new era.

Valgen Medtech Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Valgen Medtech Rank

Valgen Medtech Frequently Asked Questions (FAQ)

  • When was Valgen Medtech founded?

    Valgen Medtech was founded in 2015.

  • Where is Valgen Medtech's headquarters?

    Valgen Medtech's headquarters is located at Hangzhou.

  • What is Valgen Medtech's latest funding round?

    Valgen Medtech's latest funding round is Series B.

  • How much did Valgen Medtech raise?

    Valgen Medtech raised a total of $133M.

  • Who are the investors of Valgen Medtech?

    Investors of Valgen Medtech include Qiming Venture Partners, Venus Medtech, China Life Investment Holding Company, DCP Capital, Lake Bleu Capital and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.